X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Biotechnology

Healthcare
$2.98 +1.49%

+$0.06 today

Market cap
$304.30M
Beta
0.37
P/E (TTM)
-5.2
EPS (TTM)
-$0.79
52W Low $1.35High $4.83

Volume 0.64M

Average 0.40M

XFOR Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

X4 Pharmaceuticals, Inc.NASDAQ: XFOR

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin narrows to -749.9%

Operating margin was -749.9% in Q1 FY2026, down 717.1 pp from a year earlier. On a trailing-twelve-month basis it was -1084.4%, down 722.3 pp year over year.

What to watch

Whether operating margin reaches the consensus estimate from 2 analysts of -106.9% for the fiscal year ending Dec 2026, up from -247.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-749.9%+173.0 pp QoQ
Last fiscal yearDec 2025
-247.4%+1176.1 pp YoY
LTMMar 2026
-1084.4%-722.3 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-717.1 pp+498.8 pp+1215.9 pp
1 year+1176.1 pp+140.5 pp-1035.6 pp
3 years—+167.5 pp—
5 years+261.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-247.4%
Year-over-year change
+1176.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How XFOR compares with its peers on the latest reported figures

  • XFOR's LTM Mar 2026 operating margin of -1084.4% is the 2nd highest of the 3 companies compared; the peer median is -30896.9%.
  • Its year-over-year change of -722.3 pp is the lowest of 3, against a peer median of +121412.8 pp.
XFOR Competitors Peer median
Operating Margin for XFOR and competitors
Company Period LTM level YoY 3-year change
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026-55.7% +28.0 pp+28.4 pp
XFORX4 Pharmaceuticals, Inc.LTM Mar 2026-1084.4% -722.3 pp—
INMBINmune Bio, Inc.FY2025-61738.0% +242797.7 pp-54799.2 pp
OKUROnKure Therapeutics, Inc.FY2025— ——
Peer median (excluding XFOR) -30896.9%+121412.8 pp-27385.4 pp

Competitors are the stored peer set for XFOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0002.56M35.11M
Cost of Revenue1.89M00797K6.26M
Gross Profit(1.89M)001.76M28.86M
Gross Margin———68.8%82.2%
Research & Development48.76M61.06M72.02M81.64M72.22M
Selling, General & Admin24.7M27.02M35.51M61.52M43.52M
Operating Expenses73.46M87.57M107.52M38.16M115.74M
Depreciation & Amortization1.89M513K419K796K1.28M
EBITDA(83.15M)(89.33M)(94.89M)(27.58M)(69.01M)
EBITDA Margin———-1078.5%-196.5%
Operating Income(75.35M)(87.57M)(107.52M)(36.4M)(86.88M)
Operating Margin———-1423.6%-247.4%
Interest Income10K219K4.58M5.77M4.58M
Interest Expense3.64M3.99M5.78M8.77M8.88M
Other Income / Expenses(13.33M)(6.27M)6.43M(739K)7.73M
Income Before Tax(88.68M)(93.84M)(101.09M)(37.14M)(79.16M)
Pre-Tax Margin———-1452.5%-225.4%
Income Tax Expense17K28K78K310K41K
Net Income(88.7M)(93.87M)(101.17M)(37.45M)(79.2M)
Net Margin———-1464.6%-225.6%
EPS (Basic)(119.58)(45.60)(17.07)(5.59)(1.87)
EPS (Diluted)(119.58)(45.60)(17.07)(5.59)(1.87)
Weighted Avg Shares858.3K2.12M5.93M6.7M42.29M
Weighted Avg Shares (Diluted)858.3K2.12M5.93M6.7M42.29M

X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Intrinsic Alpha fair value

Locked

Current Price

$2.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.